FDA Brief

Warning letters Drugs

FDA warning letter to

Latin Foods Market

High riskIssued Oct 28, 2022Posted Nov 1, 2022Center for Drug Evaluation and Research | CDER

Latin Foods Market sold Artri King Reforzado con Ortiga y Omega 3, an unapproved drug with undeclared diclofenac and dexamethasone.

What happened

FDA purchased a sample of Artri King Reforzado con Ortiga y Omega 3 through Latin Foods Market's website and reviewed its labeling. Laboratory analysis confirmed the product contained diclofenac and dexamethasone, which were not declared on the label. The label also made drug claims, such as that it fights arthritis and is anti-inflammatory and analgesic.

What FDA found

  1. The product is an unapproved new drug—a drug without FDA approval—because it claims to treat arthritis and joint problems.

    FD&C Act section 505(a), 21 U.S.C. 355(a)
  2. The product is misbranded—its label is false or misleading—because it does not disclose that it contains diclofenac and dexamethasone.

    FD&C Act section 502(a), 21 U.S.C. 352(a)
  3. Selling or shipping the unapproved drug across state lines is prohibited.

    FD&C Act sections 301(d) and 505(a), 21 U.S.C. 331(d) and 355(a)
  4. Selling or shipping the misbranded drug across state lines is prohibited.

    FD&C Act section 301(a), 21 U.S.C. 331(a)

What FDA wants

FDA asks the company to submit a written response within 15 working days of receipt explaining the steps it has taken to fix the violations and prevent recurrence, with supporting documents.

Who should pay attention

  • retailers and websites selling Artri or Ortiga joint products
  • consumers who bought Artri King from Latin Foods Market
  • distributors of supplement-style products that make drug claims

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Ong Tien USA LLC

    FDA warned Ong Tien USA LLC that its herbal joint products are unapproved drugs and one contained hidden piroxicam and dexamethasone.

    High risk
  2. Jing Cheong Asia Inc. dba New York Tong Ren Tang

    New York Tong Ren Tang marketed unapproved new drugs, including eye drops, on its website.

    High risk
  3. Phuoc Loc Tho Herbals, Inc.

    FDA warned Phuoc Loc Tho Herbals that its herbal products are unapproved new drugs marketed with disease claims.

    High risk
  4. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk